Takeda and Protagonist Submit NDA to FDA for Rusfertide in Polycythemia Vera Treatment
Takeda and Protagonist File NDA for Rusfertide in Polycythemia Vera Takeda Pharmaceutical Company Limited and Protagonist Therapeutics, Inc. have announced the submission of a New Drug Application (NDA) to the…
Bayer Secures Breakthrough Therapy Designation in the U.S. and China for Sevabertinib in HER2-Mutant NSCLC
Bayer Regulatory milestones build on FDA’s recent accelerated approval for previously treated HER2-mutant lung cancer patients Bayer announced that regulatory authorities in both the United States and China have granted…
Natera Shares Updated Findings From the ALTAIR Clinical Trial at ASCO GI
Analyses provide deeper insights into outcomes from the ALTAIR study presented at ASCO GI Natera, Inc., a global leader in cell-free DNA and precision medicine, announced that updated analyses from…
Halozyme and Skye Bioscience Enter Global Collaboration to Assess Nimacimab with ENHANZE for Obesity Treatment
Global Licensing Deal Sees Halozyme and Skye Bioscience Partner on Nimacimab-ENHANZE® Obesity Program Halozyme Therapeutics, Inc. and Skye Bioscience, Inc. have disclosed that they entered into a non-exclusive worldwide collaboration…
Orum Therapeutics Names Chad May Chief Scientific Officer
Orum Therapeutics Appoints Chad May as Chief Scientific Officer to Drive Degrader-Antibody Conjugate Innovation and Programs BOSTON & DAEJEON, South Korea a biotechnology company pioneering the field of degrader-antibody conjugates…
Ironwood Pharmaceuticals Confirms FY 2025 Financial Outlook and Provides FY 2026 Financial Projections
Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance BOSTON a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare…
Johnson & Johnson Acquires Halda Therapeutics to Advance Next-Gen Oral Cancer Therapies
Johnson & Johnson Acquires Halda Therapeutics, Gaining Innovative Platform to Transform Cancer Treatment and Advance Next-Generation Oral Therapies Johnson & Johnson today announced the successful completion of its acquisition of Halda…
CRISPR Therapeutics Updates on Zugo-cel in Autoimmune & Blood Cancers
CRISPR Therapeutics Delivers Comprehensive Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) for Autoimmune Diseases and Blood Cancers CRISPR Therapeutics, a biopharmaceutical company focused on creating transformative gene-based medicines for serious…
WHO Global Summit Sets a Bold Vision for the Future of Traditional Medicine
WHO Global Summit Forges a Bold Vision for the Future of Traditional Medicine The second WHO Global Summit on Traditional Medicine, jointly organized with the Government of India, concluded today in New Delhi,…
Japan Approves Finerenone for Chronic Heart Failure Treatment
Finerenone Receives Approval in Japan for Chronic Heart Failure Treatment Bayer today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved finerenone (Kerendia™), a non-steroidal, selective mineralocorticoid…
Pimicotinib Approved in China as First Systemic Therapy for Tenosynovial Giant Cell Tumor
Pimicotinib Gains Approval in China as First Systemic Therapy for Tenosynovial Giant Cell Tumor Merck, a leading science and technology company, announced today that following Priority Review, the China National…
FDA Approves Subcutaneous Use of Roche’s Lunsumio VELO™ for Relapsed or Refractory Follicular Lymphoma
FDA Approves Subcutaneous Form of Roche’s Lunsumio VELO™ for Relapsed or Refractory Follicular Lymphoma Roche announced today that the US Food and Drug Administration (FDA) has approved CD20xCD3 bispecific Lunsumio…